Liberate Medical, LLC news
Applying non-invasive electrical stimulation to the expiratory abdominal muscles may reduce abdominal muscle atrophy and markedly reduce the number of days adult patients require mechanical ventilation – a potentially important finding for weaning ventilated patients, including seriously ill COVID-19 patients, and improving patient outcomes.
Liberate Medical today announced the results of a second randomized controlled pilot trial of its proprietary medical device, the Ven
Liberate Medical today announced that it has received Federal Drug Administration (FDA) Emergency Use Authorization for its VentFree™ Respiratory Muscle Stimulator, intended to be used to reduce disuse atrophy of the abdominal wall muscles, which may reduce the number of days adult patients require mechanical ventilation, including those patients with COVID-19.
Reducing the time patients spend on mechanical ventilation may reduce the risks of prolonged mechanical ventilation, wh
Liberate Medical, a medical device company developing novel non-invasive electrical muscle stimulation devices to help patients with pulmonary conditions, today announced that it has received CE marking for its VentFree™ Respiratory Muscle Stimulator and ISO 13485 certification for its quality management system.
The VentFree stimulator applies proprietary non-invasive electrical stimulation to the abdominal muscles during exhalation. VentFree is intended to prevent abdominal mus
Liberate Medical, a clinical-stage medical device company, developing novel electrical muscle stimulation devices that non-invasively address pulmonary conditions, today announced the results from its recently completed pilot trial of the VentFree Muscle Stimulator during an oral presentation at the American Thoracic Society International Conference (“ATS”) in Dallas, TX.
Liberate Medical, a clinical stage medical device company, focused on the development of novel non-invasive neuromuscular electrical stimulation devices to address pulmonary conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s VentFree muscle stimulator. The proposed indication for the device is preventing breathing muscle atrophy and reducing the number of days of ventilator support in adults who requ